Conflicts of interest (COI) & CRO belong to the pharmaceutical Company (CRO b2Ph [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2022-07-07 22:48 (149 d 16:33 ago) – Posting: # 23114
Views: 1,157

Dear Ohlbe ,Divyen & all,

Yes, the pot is full and this calls us (Regulatory + Industry) to unite to fight those types of frauds, otherwise, the patient will lose complete confidence in the drugs, especially the Generic drugs.
But let us return to the main topic, should the regulatory authorities refuse the submission and acceptance of BE studies that have been performed in a CRO belonging to the sponsor? are there any references? or are there other opinions other than that?

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,428 posts in 4,694 threads, 1,598 registered users;
22 visitors (1 registered, 21 guests [including 9 identified bots]).
Forum time: 14:21 CET (Europe/Vienna)

Operational hectic replaces
intellectual calms.    Alexander Huiskes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5